Autopsy report · NCT04808362

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

“Phase 1completed; sponsor decided to change strategy to a combination study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 8 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Peptomyc S.L.

Sponsor type

Industry

Conditions

Advanced Solid Tumors; Pancreatic Cancer; CRC

Interventions

OMO-103

Participants

22

Sites

3

Countries

Spain

Trials that died the same way

• Reparixin in COVID-19 Pneumonia - Efficacy and Safety
  “The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.” (70% match in meaning)
• A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
  “Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.” (67% match in meaning)
• Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
  “Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.” (65% match in meaning)
• Evaluating Return to Continence and Potency Following Radical Prostatectomy
  “The sponsor decided to not move forward with this study” (64% match in meaning)
• Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
  “Sponsor has designed another study with different endpoint to replace the current study” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.